Uscom Limited (ASX:UCM) today announced the signing of a development and supply agreement with A&D Limited of Japan.
What are the key highlights?
- The agreement relates to new technology being installed in the patented protected Uscom BP+ central blood pressure monitor.
- This supply agreement comes as the BP+ approaches regulatory approval in China and the US, and as Uscom transitions to volume manufacturing to meet the anticipated increased BP+ demand. The A&D module will be included in all new BP+ devices.
- The BP+ advanced central blood pressure (BP) monitor and its stand alone software, the BP+ Reporter, provides new information to improve diagnosis and management of hypertension and vascular health.
- A&D (Analogue and Digital) are a Tokyo based multinational company engaged in the development, manufacture and sale of precision measurement instruments in the Industrial and Medical and Health care sector. A&D was founded in 1977, and reported an annual revenue of ~$600m AUD in 2018, of which approximately 1/3rd was from the Medical and Health care sector, and it was capitalised at a value of ~$15B AUD on the Tokyo Stock Exchange.